Whereas loss of p53 function through alterations in the p53 gene or in genes encoding components of the p53 pathway (MDM2, p14ARF, etc.)is nearly universal in human cancer (4), nearly 70% of NSCLC tumors retain a mutated p53 allele encoding a missense mutated or truncated p53 protein that may display emergent oncogenic functions (hereafter noted as “Onc-p53”; 5–9). This evidence concerns the gene TP53 and cancer.